#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Colorectal cancer metastatic Obesity Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Aplastic anaemia Transitional cell cancer of the renal pelvis and ureter Precursor T-lymphoblastic lymphoma/leukaemia recurrent Polymyositis Angiosarcoma Diffuse large B-cell lymphoma refractory Chronic hepatitis B PIK3CA related overgrowth spectrum T-cell lymphoma Neuropathic arthropathy Ornithine transcarbamoylase deficiency Antiphospholipid syndrome Colitis ulcerative Heart disease congenital Von Hippel-Lindau disease More trials…

    Learn about Rare Diseases

    Myelodysplastic syndrome with excess blasts – Diagnostics Primary biliary cholangitis – Basic Information Lymphatic malformation – Diagnostics Extranodal marginal zone B-cell lymphoma (MALT type) – Diagnostics Idiopathic inflammatory myopathy – Basic Information Focal segmental glomerulosclerosis – Diagnostics Usher’s syndrome – Trials in Disease Undifferentiated sarcoma – Basic Information Inclusion body myositis – Trials in Disease Mantle cell lymphoma stage IV – Basic Information More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Tobevibart Evg321 Alxn2220 Bnt314 Epinephrine Bitartrate GSK5460025A SC0062 Incb000928 Mycophenolate Mofetil Amb-05X Alendronate Sodium Monohydrate Ivospemin Oleclumab Futibatinib Esketamine Hydrochloride Tyra-300-B01 Ranibizumab Xaluritamig Dextromethadone Hydrochloride Olaparib More therapies…

    Learn about Your Condition

    Endometriosis Tuberculosis Ventricular extrasystoles Chronic hepatic failure Cholangiocarcinoma Intestinal infarction Pulmonary tuberculosis Acute on chronic liver failure Gastric cancer recurrent Glycogen storage disorder Laparoscopic surgery Malignant melanoma stage II Extraskeletal ossification Encephalopathy neonatal Corneal graft failure More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Medical University Of Lausitz Carl Thiem

Medical University Of Lausitz Carl Thiem

Thiemstrasse 111, Spremberger Vorstadt, Cottbus, 03048, Germany

Want to learn more about this study or check if you can participate? Contact us.

  • Study of LY3484356 (imlunestrant) with Tamoxifen Citrate and Goserelin Acetate in Premenopausal Women with ER‑Positive, HER2‑Negative Early Breast Cancer

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Breast neoplasm
    Investigated Drugs:
    • Ly3484356
    • Goserelin Acetate
    • Tamoxifen Citrate
    Belgium France Germany Italy

  • Accelerating improvement with teclistamab plus standard drug combination in newly diagnosed transplant‑eligible multiple myeloma patients

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Teclistamab
    • Bortezomib
    • Daratumumab
    Germany

  • A study to evaluate the effectiveness and safety of remibrutinib in patients with secondary progressive multiple sclerosis

    Recruiting

    3 1
    Investigated Diseases:
    • Secondary progressive multiple sclerosis
    Investigated Drugs:
    • Remibrutinib
    Austria Belgium Bulgaria Croatia Czechia Denmark +19

  • Study of Ziftomenib with drug combinations for adults with newly diagnosed acute myeloid leukemia with NPM1 or KMT2A genetic changes

    Recruiting

    3 1 1
    Investigated Drugs:
    • Ziftomenib
    • Daunorubicin Hydrochloride
    • Azacitidine
    Belgium Czechia France Germany Greece Hungary +4

  • Study of ribociclib with or without chemotherapy for patients with hormone receptor positive, HER2 negative early breast cancer at intermediate risk

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Hormone receptor positive HER2 negative breast cancer
    Investigated Drugs:
    • Epirubicin
    • Leuprorelin
    • Anastrozole
    France Germany Italy The Netherlands Spain

  • Study of risankizumab safety and effectiveness in children and teenagers aged 2-17 years with moderate to severe ulcerative colitis

    Recruiting

    3 1
    Investigated Diseases:
    • Colitis ulcerative
    Investigated Drugs:
    • Risankizumab
    Belgium Germany Greece Italy Spain Sweden

  • Long-term Safety and Efficacy Study of JR-141 (Pabinafusp Alfa) for Male Patients with Hunter Syndrome (Mucopolysaccharidosis II)

    Recruiting

    3 1 1
    Investigated Diseases:
    • Mucopolysaccharidosis II
    Investigated Drugs:
    • Pabinafusp Alfa
    France Germany Italy Poland Spain

  • Study Comparing Elranatamab to Drug Combinations for Patients with Relapsed/Refractory Multiple Myeloma After Anti-CD38 Therapy

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Plasma cell myeloma refractory
    Investigated Drugs:
    • Elranatamab
    • Bortezomib
    • Carfilzomib
    Belgium Croatia Czechia Denmark Finland France +10

  • Study on Fazirsiran for Patients with Alpha-1 Antitrypsin Deficiency-Related Liver Disease and Fibrosis

    Recruiting

    3 1 1
    Investigated Drugs:
    • Fazirsiran
    • Saline
    Austria Belgium Czechia Denmark France Germany +7

  • Study on Long-Term Safety of Fazirsiran for Patients with Alpha-1 Antitrypsin Deficiency-Related Liver Disease

    Recruiting

    3 1 1
    Investigated Drugs:
    • Fazirsiran
    Austria Germany Portugal
1 2
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!